Aims Echocardiography has shown to categorize heart failure (HF) patients according to
haemodynamic profiles. Whether left ventricular (LV) global longitudinal strain (LV-GLS) …

Background Sacubitril/valsartan has been highly efficacious in randomized clinical trials of
patients with HFrEF. However, the effectiveness of sacubitril/valsartan in routine US clinical …

Objectives: The purpose of this study was to compare outcomes (and the effect of
sacubitril/valsartan) according to etiology in the PARADIGM-HF (Prospective comparison of …

Background Sacubitril/Valsartan has been highly efficacious in randomized trials of heart
failure with reduced ejection fraction (HFrEF). However, the effectiveness of …

Background Sacubitril/valsartan has been shown to improve mortality and reduce
hospitalizations in patients with heart failure (HF) with reduced ejection fraction (HFrEF) …

Background: The net clinical benefit of cardiac disease-modifying drugs might be influenced
by the interaction of different domains of disease burden. We assessed the relative …

Objectives This study investigated the prognostic importance of heart failure (HF) signs and
symptoms in patients with heart failure and preserved ejection fraction (HFpEF), and the …

Sacubitril/valsartan (Sac/Val) reduces mortality in patients with heart failure with reduced
ejection fraction (HFrEF) compared to enalapril. However, its effects on functional capacity …

Background Little information is available about the tolerability of uptitration to the maximal
dose of sacubitril/valsartan and the predictors and clinical correlates of achieving such a …

Objective In this post hoc analysis of the PARAGON-HF (Prospective Comparison of ARNI
with ARB Global Outcomes in HFpEF) trial, we evaluated clinical outcomes and responses …